NCT05527405

Brief Summary

As part of Phase II of the NIH SBIR grant, the study will conduct a randomized controlled clinical trial in which the MapHabit system (MHS) will offer a caregiver training product that is linked to MHS, an Alzheimer's disease or related dementias (AD/ADRD) assistive technology product that uses visual maps to improve a patient's behavior and sense of autonomy. MapHabit's combined areas of focus, i.e., offer a single integrated product to address the caregiver and the person under this caregiver's care, are unique and will create a new standard in the field to reduce caregiver burden in the setting of caring for individuals with AD/ADRD. Additionally, the study will integrate enhanced user support modules, i.e., gamifying, dashboarding, and social networking, to improve the Caregiver Training Program (CTP) experience.The study will be a randomized controlled clinical trial, in which two conditions will be investigated: 1) control condition in which the MHS alone is incorporated in the participant's daily care and 2) experimental condition in which the MHS+CTP is implemented into the daily care received by participants. The sample size will be a total of 50 patient-caregiver dyads, 25 in each condition. The study duration will be a 6-month intervention.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable alzheimer-disease

Timeline
Completed

Started Aug 2024

Shorter than P25 for not_applicable alzheimer-disease

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 31, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 2, 2022

Completed
2 years until next milestone

Study Start

First participant enrolled

August 24, 2024

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

October 2, 2025

Status Verified

September 1, 2025

Enrollment Period

1.3 years

First QC Date

August 31, 2022

Last Update Submit

September 28, 2025

Conditions

Keywords

Alzheimer DiseaseDementiaCaregiver BurdenActivities of Daily LivingAssistive Technology

Outcome Measures

Primary Outcomes (6)

  • Change in User Interaction and Engagement from baseline at 6 months

    18-item quality-of-life questionnaire (QoL-18) evaluates a range of participants' behaviors, including mood, engagement, and memory at the end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.

    Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

  • Change in Zarit Burden Assessment Caregiver Strain instrument from baseline at 6 months

    18-item questionnaire assessing the various stresses caregivers experienced relating to caring for an individual with cognitive impairment. The total score ranges from 0-72, with a higher score reflecting higher stress and burden on the caregiver.

    Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

  • Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) from baseline at 6 months

    Assesses an individual with dementia's ability to carry out activities of daily living. The total score ranges from 0-53, with a higher score representing better performance in completing activities of daily living by the individual with dementia.

    Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

  • Change in Quality of Life - 18 (QoL-18) from baseline at 6 months

    18-item quality-of-life questionnaire (QoL-18) evaluated a range of participants' behaviors, including mood, engagement, and memory at the middle and end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.

    Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

  • Change in Brief Quality of Life - 8 (QoL-8) from baseline at 6 months

    8-items selected from the Wisconsin Quality of Life Caregiver Questionnaire evaluated a range of participants' behaviors, including mood, engagement, and memory at the middle and end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.

    Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

  • Change in Caregiver Self-Assessment Questionnaire from baseline at 6 months

    12-item, caregiver self-report measure of stress levels

    Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

Secondary Outcomes (4)

  • 2-item Satisfaction Scale (SS-2)

    The instrument was administered to the participants after the completion of the study duration (i.e., assessed at 6 months)

  • Pain and Sleep Questionnaire

    Pre-Post: The assessment will be administered at baseline, post-intervention (6 months)

  • Generalized Anxiety Disorder (GAD7) Scale

    Pre-Post: The assessment will be administered at baseline, post-intervention (6 months)

  • Anger Management Scale

    Pre-Post: The assessment will be administered at baseline, post-intervention (6 months)

Study Arms (2)

Caregiver Training Program

EXPERIMENTAL

This condition will involve the implementation of an assistive technology software (named the MapHabit System) with an added Caregiver Training Program into the daily care of individuals with mild to moderate stages of Alzheimer's disease and related dementias. The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.

Device: The MapHabit System

The MapHabit System

ACTIVE COMPARATOR

This control condition will act as the active comparator to the experimental condition. The same assistive technology, the MapHabit System, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include the caregiver training program.

Device: The MapHabit System

Interventions

The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available through tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified structure and the Caregiver Training Program. The MHS is a general wellness product. This functionality is not a regulated medical device.

Caregiver Training ProgramThe MapHabit System

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individual diagnosed with Alzheimer's disease or other related dementia (ADRD) in their mild to moderate stage of impairment
  • Participating caregiver of individual with dementia must be the primary caregiver
  • Proficient in English

You may not qualify if:

  • Individual not diagnosed with ADRD
  • Participating caregiver of individual with dementia is NOT the primary caregiver
  • Not proficient in English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MapHabit, Inc.

Atlanta, Georgia, 30308, United States

Location

Related Publications (3)

  • Boatman F, Golden M, Jin J, Kim Y, Law S, Lu A, Merriam N, Zola S. Assistive technology: Visual mapping combined with mobile software can enhance quality of life and ability to carry out activities of daily living in individuals with impaired memory. Technol Health Care. 2020;28(2):121-128. doi: 10.3233/THC-191980.

    PMID: 31796718BACKGROUND
  • Kelleher J, Zola S, Cui X, Chen S, Gerber C, Parker MW, Davis C, Law S, Golden M, Vaughan CP. Personalized Visual Mapping Assistive Technology to Improve Functional Ability in Persons With Dementia: Feasibility Cohort Study. JMIR Aging. 2021 Oct 19;4(4):e28165. doi: 10.2196/28165.

    PMID: 34269690BACKGROUND
  • Parker MW, Davis C, White K, Johnson D, Golden M, Zola S. Reduced care burden and improved quality of life in African American family caregivers: Positive impact of personalized assistive technology. Technol Health Care. 2022;30(2):379-387. doi: 10.3233/THC-213049.

    PMID: 34334439BACKGROUND

MeSH Terms

Conditions

Alzheimer DiseaseDementiaCaregiver Burden

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersStress, PsychologicalBehavioral SymptomsBehavior

Study Officials

  • Stuart Zola

    MapHabit, Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Statistical analyses of all data will be carried out independently of investigators by a biostatistical resource department of an academic health center for validation.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: The study will be a randomized controlled clinical trial in which two conditions will be investigated: a control and an experimental condition.
Sponsor Type
INDUSTRY
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Scientific Officer

Study Record Dates

First Submitted

August 31, 2022

First Posted

September 2, 2022

Study Start

August 24, 2024

Primary Completion

November 30, 2025

Study Completion

December 31, 2025

Last Updated

October 2, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

All of the individual participant data collected during the trial, after deidentification.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Immediately following publication. No end date.
Access Criteria
Researchers who provide a methodologically sound proposal. Proposals should be directed to szola@maphabit.com. To gain access, data requestors will need to sign a data access agreement.

Locations